John Lunger
2021
In 2021, John Lunger earned a total compensation of $1.7M as Chief Operating Officer at Adaptimmune Therapeutics, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $183,825 |
|---|---|
| Option Awards | $1,069,101 |
| Salary | $430,000 |
| Other | $32,083 |
| Total | $1,715,009 |
Lunger received $1.1M in option awards, accounting for 62% of the total pay in 2021.
Lunger also received $183.8K in non-equity incentive plan, $430K in salary and $32.1K in other compensation.
Rankings
In 2021, John Lunger's compensation ranked 6,679th out of 12,406 executives tracked by ExecPay. In other words, Lunger earned more than 46.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,679 out of 12,406 | 46th |
Division Manufacturing | 2,890 out of 5,494 | 47th |
Major group Chemicals And Allied Products | 1,271 out of 2,369 | 46th |
Industry group Drugs | 1,133 out of 2,090 | 46th |
Industry Biological Products, Except Diagnostic Substances | 271 out of 452 | 40th |
Pay ratio
| John Lunger's Pay | $1,715,009 |
|---|---|
| Median Employee's Pay | $126,493 |
| Pay Ratio | 14to 1 |
In 2021, the annual total compensation of John Lunger was $1,715,009.
The annual total compensation of the median employee at Adaptimmune Therapeutics was $126,493.
The ratio of John Lunger's pay to the pay of median employee was therefore 14 to one.
Source: SEC filing on April 21, 2022.
Lunger's colleagues
We found four more compensation records of executives who worked with John Lunger at Adaptimmune Therapeutics in 2021.